Fifth Basic Sciences Symposium of the Transplantation Society

The Fifth Basic Sciences Symposium of the Transplantation Society will be held at the Chautauqua Institution, Chautauqua, NY, on September 6–11, 1997. Distinguished plenary speakers will update the most relevant topics of transplantation biology, which will be enhanced by oral and poster presentations by interested participants on the following subjects: T-Cell Stimulation and Co-stimulation, T-Cell Signalling Mechanisms, Immune Privilege, Tolerance, Chimerism and Bone Marrow Transplantation, Immunosuppression, Alloreactivity and Rejection, and Newer Experimental Models. The deadline for submission of abstracts was January 31, 1997. For further information, contact R. Cunningham, Ph.D., The Ernest Witebsky Center for Immunology, School of Medicine and Biomedical Sciences, 233 Sherman Hall, 3435 Main Street, Buffalo, NY 14214-3078. Telephone: 716/829-2901; fax: 716/829-2158; e-mail: rcunning@ubmedb.buffalo.edu.

Second Congress of BANTAO (Balkan Cities Association of Nephrology, Dialysis, Transplantation and Artificial Organs)

The Second Congress of BANTAO will be held September 6–8, 1997, in Struga, Republic of Macedonia. The Congress is sponsored by the European Society for Artificial Organs (ESAO), the International Faculty for Artificial Organs (IFAO). The primary topics of the Congress will be epidemiology of renal diseases; acute renal failure (etiopathogenesis and treatment); renal replacement therapy; systemic disease and renal involvement; progress in nephrology (invited symposium); and drugs and the kidney. For further information, contact Prof. M. Polenakovic, Department of Nephrology, Clinical Centre, Medical Faculty, Vodnianska 17, 91000 Skopje, R. Macedonia. Telephone: +389 91 112 179; fax: +389 91 614 486; e-mail: maknefpo@lotus.mpt.com.mk.

Second Congress of the Macedonia Society of Nephrology, Dialysis, Transplantation and Artificial Organs

The Second Congress of the Macedonian Society of Nephrology, Dialysis, Transplantation and Artificial Organs will be held September 8–10, 1997, in Struga, Republic of Macedonia. The Congress is sponsored by the European Society for Artificial Organs (ESAO), the International Society for Artificial Organs (ISAO). The primary topics of the Congress will be: epidemiology of renal diseases in the Republic of Macedonia; acute renal failure (etiopathogenesis and treatment); dialysis; pregnancy and the kidney; urinary tract infections; primary and secondary glomerulonephropathies; hypertension; ultrasounds in nephrology; and renal transplantation. For further information, contact Prof. M. Polenakovic, Department of Nephrology, Clinical Centre, Medical Faculty, Vodnianska 17, 91000 Skopje, R. Macedonia. Telephone: +389 91 112 179; fax: +389 91 614 486; e-mail: maknefpo@lotus.mpt.com.mk.

NIDDK Polycystic Kidney Disease (PKD) Workshop

The National Institute of Diabetes and Digestive and Kidney Diseases will hold a Polycystic Kidney Disease (PKD) Workshop at the National Institutes of Health in Bethesda, Maryland, September 10–11, 1997. For information, contact Ms. Andrea Gasper, CCC. Telephone: (301) 493-9674; fax: (301) 493-9674; e-mail: andreag@ccc76.com.

15th Annual Meeting of the International Society of Blood Purification (ISBP)

The 15th Annual Meeting of the International Society of Blood Purification (ISBP) will be held September 11–13, 1997, in Florence, Italy. Topics will include symposia on the myocardium in chronic renal failure, the present status of peritoneal dialysis, and novels from erythropoietin developments. For further information, please contact Prof. Q. Maggiore, Nephrology Unit, S.M. Annunziata Hospital, 50011, Florence, Italy. Fax: +39 55 6449223; e-mail: q.maggiore@trident.netuno.it.

Renal Biopsy in Medical Diseases of the Kidney

Renal Biopsy in Medical Diseases of the Kidney will be held September 24–27, 1997, at the Columbia-Presbyterian Medical Center, New York, NY. The accredited sponsor for the course is the College of Physicians & Surgeons of Columbia University. Program directors Gerald B. Appel, M.D., Vivette D. D’Agati, M.D., Conrad L. Pirani, M.D., and Fred G. Silva, M.D. will be joined by guest lecturers Charles E. Alpers, M.D., Robert B. Colvin, M.D., William G. Couser, M.D., Agnes Fogo, M.D., Eli Friedman, M.D., Gloria Gallo M.D., Gary S. Hill, M.D., J. Charles Jennette, M.D., Marc A. Pohl, M.D., Helmut G. Renneke, M.D., Burton D. Rose, M.D., Fred G. Silva, M.D., and C. Craig Tisher, M.D. The intensive course is designed for pathologists, nephrologists, internists, and other physicians interested in both a systematic review and an update on advances in diagnostic problems in medical renal diseases. The course should be of special interest to physicians who are preparing for their specialty Board Examinations in Pathology and Clinical Nephrology. Clinico-pathological correlations will be emphasized. The format includes lectures, question-and-answer sessions, and the study of case problems. An optional 4-hour renal pathology laboratory exercise is available on Saturday afternoon after the conclusion of the formal lectures. Tuition fees are $595 for physicians, and $395 for fellows and residents in training. These fees include the academic presentations and laboratory session, course syllabus, Kodachrome slides, electronmicrographs of "classic" renal lesions, daily continental breakfast, luncheon, and refreshments. The course satisfies 27.5 CME credits in Category 1, A.M.A.'s Physician's Recognition Award. For further information, contact the Center for Continuing Education, College

24th Congress of the European Society For Artificial Organs
The 24th Congress of the European Society For Artificial Organs will be held October 16–18, 1997, in Budapest, Hungary. Main topics will include the pathophysiology of clinical applications of artificial organs, improvement in material properties as a prerequisite for the development of artificial organs, and the importance of auxiliary treatment in artificial organ therapy. For further scientific information, please contact Judit Walter, MD, PhD, President of ESAO 97, Selyemerdő u. l., 6300 Kalocsa, Hungary. Telephone: +36/78/462-782; fax +36/78/465-077. For general information by computer, e-mail: Novis@elender.hu; http://www.elender.hu/~novis/esafo.

1st International Congress on Immunointervention in Nephrology
The 1st International Congress on Immunointervention in Nephrology, organized by the Department of Nephrology, Ospedale S. Michele, Cagliari, Italy (P. Altieri, M.D.), and the Division of Nephrology, Ospedale Maggiore IRCCS, Milan, Italy (C. Ponticelli, M.D.), will be held April 30–May 2, 1998, in Cagliari, Sardinia, Italy. The meeting will deal with new therapeutic strategies in kidney transplantation and with clinical and therapeutic aspects of lupus nephritis. Tuition is 250 US$. The deadline for abstract presentation is January 15, 1998. For information contact: Paolo Altieri, M.D., Dipartimento di Nefrologia e Dialisi, Ospedale S. Michele, Via Peretti, 09134 Cagliari (Italy). Telephone and fax: +39-70-542872 or +39-70-539491.

XVII World Congress of The Transplantation Society
The XVII World Congress of The Transplantation Society will be held July 12–17, 1998, in Montréal, Canada. The deadline for abstract submission is January 19, 1998. For further information, please contact Lucy Felicissimo & Associates, Inc., 12,449 rue Cousineau, Montréal, Quebec, Canada H4K 1P9. Fax: 514-334-5200.
Cardiazem is concomitantly administered, it has been reported to result in elevated serum levels of carboxyhemoglobin (40% to 75% increase), resulting in toxicity in some cases. Patients receiving these drugs concurrently should be monitored for a potential drug interaction.

**Concomitant Administration of CARDIZEM with Other Drugs:**

**Cyclosporine:** Studies have shown that concomitant administration of CARDIZEM and cyclosporine has been reported to result in elevated serum levels of cyclosporine, which may lead to toxicity in some cases. Patients receiving these drugs concurrently should be monitored for a potential drug interaction.

**ACE Inhibitors:** Studies have shown that concomitant administration of CARDIZEM and ACE inhibitors has been reported to result in elevated serum levels of ACE inhibitors, which may lead to toxicity in some cases. Patients receiving these drugs concurrently should be monitored for a potential drug interaction.

**Oral Anticoagulants:** Studies have shown that concomitant administration of CARDIZEM and oral anticoagulants has been reported to result in elevated serum levels of oral anticoagulants, which may lead to toxicity in some cases. Patients receiving these drugs concurrently should be monitored for a potential drug interaction.

**Cardizem Concomitant Administration Summary**

Concomitant administration of CARDIZEM and other drugs has been reported to result in toxicities, which may lead to adverse effects in some cases. Patients receiving these drugs concurrently should be monitored for a potential drug interaction.

**Adverse Reactions**

**Clinical Trials:**

In clinical trials of CARDIZEM capsules, tablets, and SR capsules involving over 2000 patients, the most common adverse events were headache, lethargy, somnolence, dizziness, asthenia, fatigue, gastrointestina, asthenia, fatigue, gastrointestinal disorders, diaphoresis, dyspnea, hypotension, palpitations, syncope, tachycardia, ventricular extrasystoles, and myalgia. The most frequently reported adverse reactions were headache, somnolence, dizziness, and asthenia.

**Concomitant Administration of CARDIZEM and Other Drugs:**

**Cyclosporine:** Studies have shown that concomitant administration of CARDIZEM and cyclosporine has been reported to result in elevated serum levels of cyclosporine, which may lead to toxicity in some cases. Patients receiving these drugs concurrently should be monitored for a potential drug interaction.

**ACE Inhibitors:** Studies have shown that concomitant administration of CARDIZEM and ACE inhibitors has been reported to result in elevated serum levels of ACE inhibitors, which may lead to toxicity in some cases. Patients receiving these drugs concurrently should be monitored for a potential drug interaction.

**Oral Anticoagulants:** Studies have shown that concomitant administration of CARDIZEM and oral anticoagulants has been reported to result in elevated serum levels of oral anticoagulants, which may lead to toxicity in some cases. Patients receiving these drugs concurrently should be monitored for a potential drug interaction.

**Cardizem Concomitant Administration Summary**

Concomitant administration of CARDIZEM and other drugs has been reported to result in toxicities, which may lead to adverse effects in some cases. Patients receiving these drugs concurrently should be monitored for a potential drug interaction.

**References**

A UNIQUE HEMODYNAMIC AND SAFETY PROFILE DIFFERENT FROM DIHYDROPYRIDINES

Effective 24-hour control of hypertension or angina
- Reduces blood pressure with no reflex tachycardia
- Increases exercise tolerance, reduces vasospasm, and decreases heart rate in angina

Well-tolerated control regardless of age or gender
- A side-effect discontinuation rate comparable to placebo
- Most commonly reported side effects are headache (5.4%), bradycardia (3.3%), first-degree AV block (3.3%), dizziness (3.0%), edema (2.6%), ECG abnormality (1.6%), and asthenia (1.8%)†

True 24-hour control from a unique patented delivery system
- No other diltiazem is therapeutically equivalent to Cardizem CD‡

*Cardizem CD is a benzothiazepine calcium channel blocker.
† In clinical trials with Cardizem CD.
‡ FDA does not, at this time, consider other diltiazems to be therapeutically equivalent because bioequivalence has not been demonstrated through appropriate studies.

Please see brief summary of prescribing information on adjacent page.

FOR HYPERTENSION OR ANGINA

ONCE-A-DAY
CARDIZEM® CD
(diltiazem HCl) 120-, 180-, 240-, 300-mg Capsules

No other diltiazem is therapeutically equivalent‡‡